Pancreatic cancer is one of the most aggressive malignancies with a very poor prognosis, partially due to its very low accessibility to resection and resistance to chemoradiotherapy. As such, it is reasonable to find more effective, specific therapies and the related therapeutic targets. The identification of certain genes contributing to the tumorigenesis and poor prognosis provides the specific targets for efficient silencing by RNA interference (RNAi). As a powerful tool to suppress gene expression in mammalian cells, RNAi can be directed against pancreatic cancer through various pathways, including the inhibition of overexpressed oncogenes, suppression of tumor growth, metastasis and enhancement of apoptosis. In combination with chemoradiotherapy agents, RNAi can also attenuate the chemoradiation resistance of pancreatic cancer. In addition, RNAi has been used to define the 'loss of function' of endogenous genes in pancreatic cancer. This review provides a brief introduction to recent developments of RNAi applications in pancreatic cancer studies and suggestions for further exploration. It substantially demonstrates that RNAi holds a promising therapeutic potential as a future treatment for pancreatic cancer.
Introduction
Pancreatic cancer is one of the most aggressive malignancies with a very poor prognosis. Despite the progress of diagnostic and surgical procedures, potentially curative surgery may be expected in only 10-15% of the ductal pancreatic cancer patients. Pancreatic carcinoma remains one of the top 10 causes of death from cancer in the Western world. 1 This malignancy currently represents the fourth leading cause of cancer deaths in the United States with a 5-year survival rate of less than 5%. More than 30 000 Americans were estimated to have died from this disease in 2004 and 2005. 2, 3 In European countries, it is the tenth most frequent cancer, accounting for 3% of cancer patients in both sexes. 4 So far, multiple molecular abnormalities, which play critical roles in tumor progression and resistance to existing chemotherapies and radiation therapy, have been identified in pancreatic cancer. [5] [6] [7] [8] Therefore, it is challenging to determine unknown molecular pathways that govern the aggressiveness of this cancer, and develop new clinical trials for improving the outcomes of pancreatic cancer patients. Gene therapy, irrespective of whether it specifically silences overexpressed oncogenes or restores the normal functions of cancer suppressor genes, has been applied successfully in the pancreatic cancer research in vitro and in vivo.
More recently, one of the most efficient ways to inhibit targeted genes is RNA interference (RNAi) technology, coined the 'Science Breakthrough of the Year' for 2002 by the Journal of Science. 9 RNAi refers to a group of related gene-silencing mechanisms, in which the terminal effector molecule is a short antisense RNA. 10 However, only after the doublestranded RNA (dsRNA) in Caenorhabditis elegans had substantially demonstrated itself to be more potent and specific at producing interference than was either strand individually, 11 more attention was paid to the discovery of this novel gene silencing.
Currently, it is already a valuable and widely used research tool in the understanding of genetic abnormalities and molecular mechanisms in diseases by silencing the targeted genes, especially in cancer research.
RNAi is a post-transcriptional gene-silencing procession by cleaving specifically sequenced mRNA to which the dsRNAs is complementary. These dsRNAs are processed and cut by the enzyme Dicer, one member of the RNase b family of ribonuclease 12 into 21-to-23-nucleotides short interfering RNAs (siRNA). The siRNAs are bound to an RNA-induced silencing complex (RISC), by which the double-stranded siRNA is unwound. Meanwhile, the antisense strand remains incorporated to the RISC and guides the complex to cleave and degrade the perfectly complementary target mRNA.
It has been confirmed that siRNAs are more stable in mammalian cells and physiological fluids, and more highly efficient in gene silencing than antisense oligodeoxyribonucleic acids (ODNAs) and ribozymes. Furthermore, after siRNAs are transfected, expression of a target gene can be reduced by as much as 10-fold with a high degree of specificity. 15, 16 Additionally, only a single point in genes can be specifically and efficiently discriminated by siRNA, leading to the destruction of a targeted mutant, whereas the wide-type one is intact. 17 Moreover, it only takes a few months to elucidate the effects of the loss of a target gene as opposed to the several years that are needed to generate knockout mice. 18 That being considered, it is much more important to make many more efforts to develop potential RNAi applications on many different biomedical fronts, particularly in cancer research. The following sections will present the recent developments of RNAi and related research, and the potentially clinical therapy targets in pancreatic cancer will be reviewed (see Table 1 ).
Molecular targets by RNAi in pancreatic cancer
Along with the development of siRNA-producing expression vectors, the stable RNAi method is considered a powerful tool for analyzing the 'loss of function' of endogenous genes in mammalian cells. Most importantly, the novel targeted molecules for cancer therapy can be subsequently addressed. Since pancreatic cancer is one of the most aggressive malignant tumors with an extremely poor prognosis, partly due to its low surgical resection rate and chemoradiotherapy resistance, it is especially critical to reveal the attributable factors to develop new therapeutic approaches with RNAi.
Targeting oncogene by RNAi
Among the genetic abnormalities that have been identified in pancreatic cancer, Ras genes are frequently muted, of which K-Ras mutations are of the highest frequency. 19, 20 Considering the importance of Ras signaling in cell proliferation and survival, it is essential to silence the expression of it with RNAi effectively and specifically by inhibiting the activity of oncogenic K-Ras, rather than that of the wide-type K-Ras protein in normal tissues. 21 By developing an siRNA retroviral vector targeting sequence in the region that encodes valine 12 of mutant K-Ras, and infecting one pancreatic cancer cell line, CAPAN-1, Brummelkamp et al. 21 revealed that the expression of mutant K-Ras was strongly and selectively suppressed, whereas that of wild one, although only one base pair differed between the two, remained a normal expression.
Most significantly, the downregulation of mutant K-Ras abolished the colony growth in vitro and tumor formation in vivo, fully demonstrating that the transfected cancer cells had lost their anchorage-dependent growth and tumorigenicity. Another study involving the abolition of activated K-Ras in two pancreatic cancer cell lines PANC-1 and MIAPACA-2, via mutant-specific siRNA, confirmed similar cellular changes consistent with a reduced malignant phenotype. Both cell lines had a decrease in cell proliferation, reduced cell migration, vascular endothelial growth factor (VEGF) reduction and colony formation after muted K-Ras knockdown, definitely indicating siRNA inhibits pancreatic cancer cells growth in vitro. Nevertheless, the molecular consequences, after selective silencing of K-Ras mutation, were not completely consistent between the two cell lines, 22 which is proposed to be related, in part, to the different expressions and activity of c-myc after the knockdown of K-Ras and the molecular interaction between Ras and c-myc in the two cell lines. This is an indication that the interaction within the RNAi needs further research.
Targeting the molecules associated with pancreatic cancer progression and angiogenesis by RNAi It has been proved that the principal characteristics of neoplastic cells consist of upregulated growth, decreased 
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apoptosis, angiogenesis induction and migration and metastasis to distant organs. Consequently, the multiple genetic alterations contributing to the malignant phenotypes have been gradually described. Therefore, blocking these molecular abnormalities by RNAi represents one potentially powerful anticancer therapy in the not too distant future. Actually, numerous molecules have been elucidated, which can be used to reverse the neoplastic phenotypes in vitro and in vivo through knockdown of the encoded genes by RNAi. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is overexpressed in some gastrointestinal tumors, which has been proven to influence intracellular signalings, especially related to promoting pancreatic cancer cell survival and metastatic potential. [23] [24] [25] Duxbury et al. 26 reported that targeting CEACAM6 with systemically administered siRNA suppressed the CEACAM6 expression, subsequently impairing the pancreatic cancer xenograft growth, metastasis and improving the survival of tumor-bearing nude mice. These therapeutic effects are associated with impaired cellular proliferation, increased apoptosis and lower levels of tumor angiogenesis.
Tissue factor (TF), also known as thromboplastin, plays a key role in coagulation and tumor progression. 27 It had already been recognized that TF was involved in the tumorigenesis of pancreatic cancer. 28 Increased TF expression has also been associated with the progression of pancreatic cancer, as far as the extent of the primary tumor, lymph metastasis and advanced stages. [29] [30] [31] [32] The subsequent knockdown of endogenous TF with siRNA suppressed the invasiveness of pancreatic cancer cell lines in vitro, which, accordingly, revealed the importance of TF in tumor invasion and the possible therapeutic implications.
Knockdown of TF via siRNA might result in the suppression of both tumor invasion and angiogenesis, in association with the function of TF-modulating VEGF expression and angiogenesis. However, the possible side effects of TF targeting therapy with RNAi, such as an increased bleeding tendency, should be considered, 29 as the research has pointed out.
One tyrosine kinase, EphA2, that is primarily expressed to a low degree in epithelial cells, 33 has been described to be overexpressed in human cancers. The overexpression of EphA2 is associated with progression and a poor prognosis of cancer. 34, 35 In their report, using EphA2-specific siRNA, Duxbury et al. found that EphA2 expression was inhibited at the post-transcriptional level and the invasiveness of pancreatic cancer cell lines was significantly reduced. Systemic administration of EphA2 siRNA also inhibited the growth and metastasis in vivo in the nude mice xenograft models through the silencing of EphA2, consistent with the effect in vitro. Coinciding with this study, another therapeutic siRNA directed against EphA2 similarly decreased the EphA2 level and tumor growth in an orthotopic mouse model of ovarian cancer. 37 Malignant cells usually survive in the hypoxic microenvironment of the tumor with an increased glucose transport, in which the expression of glucose transporter-1 (GLUT-1) is reportedly upregulated. [38] [39] [40] [41] [42] GLUT-1 has been demonstrated to be overexpressed in pancreatic cancer, which promotes pancreatic cancer invasion and metastatic potential with activation and upregulation of matrix metalloproteinase-2 (MMP-2). Although, after the transfection with a vector encoding GLUT-1 siRNA which stably silenced the expression of GLUT-1, no significant changes were found in cell viability or proliferation in pancreatic cancer cell lines; whereas, the knockdown of GLUT-1 absolutely inhibited liver metastasis in vivo in the nude mice models, in which the downregulation of MMP-2 induced by silencing GLUT-1 might account for the antimetastasis. 42 Collectively, all the above-mentioned molecules could be considered to be the therapeutic targets of RNAi. Hence, as far as seeking new therapeutic agents of pancreatic cancer is concerned, based on the specific knockdown of target genes by RNAi, it is only if the genes are overexpressed leading to tumorigenesis, angiogenesis and invasiveness in pancreatic cancer, there is no doubt that they can become the attractive candidates for RNAi.
Targeting chemoradiotherapy resistance-associated genes by RNAi
Despite the innovation of recent therapeutic methods, pancreatic cancer remains one of the leading causes of cancer-related deaths in the world. Aside from the low accessibility of surgical resection due to the results of advanced stages when being diagnosed, another critical attribute associated with the poor prognosis arises from the resistance and insensitivity of this kind of malignancy to conventional chemotherapy, radiotherapy and immunotherapy. 43, 44 Therefore, it is obviously urgent and expedient to devise substantial solutions to restore the sensitivity of pancreatic cancer cells to conventional chemoradiotherapy. Fortunately, the emergence of RNAi technology has been proven to be a viable option.
Various mechanisms of drug resistance have been proposed. P-glycoprotein (P-gp) encoded by the multidrug resistance (MDR)-1 gene, is the best-defined multidrug transporter protein, which plays a crucial role in conferring resistance to anticancer agents. Hence, sensitivity of tumor cells to chemotherapy may be regained by disruption or inhibition of P-gp mediated drug resistance. siRNA has been proved to counteract such resistance to chemotherapy by suppressing the expression of MDR-1 gene-encoded P-gp in pancreatic cancer. 45 More recently, drug resistance in some other malignant cell lines has been restored by siRNA-targeted knockdown of MDR-1 gene. [46] [47] [48] [49] Nieth et al. 45 report that the 21-nt siRNA directed against P-gp decreased its expression at mRNA, as well as the protein level in pancreatic cancer cell line EPP85-181RDB. Moreover, the drug-resistant phenotype was also reversed by RNAi, and malignant cell line resistance against Daunorubin was obviously decreased to 89%, proving that siRNA-targeted silencing of P-gp expression might be an effective method for the reversal of drug resistance in pancreatic cancer patients.
Additionally, another mechanism accounting for the chemoradiotherapy resistance, at least in part, is antiapoptosis of malignant cells. Moreover, most of the therapeutic, anticancer strategies currently available, including chemotherapy and radiotherapy, practically rely on the induction of apoptosis to eliminate the malignant cells. 50 However, owing to the overexpression of antiapoptosis proteins, most kinds of malignancies are characterized to have increased the resistance to apoptosis, and consequently, the ability that enables the malignant cells to overcome the apoptosis triggered by chemoradiotherapy agents. Increasing evidence indicates that X-linked inhibitor of apoptosis (XIAP), Survivin and Livin, members of inhibitors of the apoptosis protein (IAP) family, are confirmed to be upregulated in many human type tumors, which, conversely, are partly crucial to the chemoradioresistance. 51, 52 Survivin overexpression correlated with poor prognoses in pancreatic cancer patients, as well as in other malignancies. 53 In addition, Survivin is also involved in tumor cell resistance to radiation therapy. 54 Therefore, Survivin can be considered as one target gene to RNAi. Kami et al. 55 found that with an increased caspase-3 activation and apoptotic index, the radiotherapy resistance of pancreatic cancer cells was diminished after the downregulation of Survivin by siRNA, suggesting that the inhibition of Survivin expression by RNAi might be combined as a reasonable approach with radiation therapy for unresectable or recurrent pancreatic cancer, based on more efficient transfection of siRNA to target cells.
Another attempt of introducing Survivin siRNA into pancreatic cancer cells also induced downregulation of Survivin expression at the mRNA and protein level, respectively, and the inhibition of cell growth. 56 Apart from Survivin, with the application of siRNA, other expressions of IAPs, including XIAP, Livin, were silenced in vitro and these IAP knockdowns have been confirmed to sensitize cancer cells to chemotherapeutics, through activating caspase-3, caspase-8 and increasing the apoptotic rate. Hence, the IAPs can be defined as a promising molecular target for the restoration of sensitivity of therapy for RNAi. [57] [58] [59] [60] [61] With respect to pancreatic cancer, the potential of RNAi targeting IAPs for treatment, in combination with widely used therapies, such as chemotherapy and radiotherapy, should be subject to further investigation in vitro and in vivo.
Other efforts for enhancing the chemosensitivity of pancreatic caner with RNAi have been made by downregulating some tumorigenesis-related genes, which are overexpressed in malignancies. Integrin-linked kinase (ILK) is a serine/threonine kinase that mediates some cell functions by coupling integrins and growth factors to cascades of downstream signaling events. 62 Overexpression of ILK in malignant tumors has been shown to be correlated with tumor progression and poor prognosis in ovarian 63 and gastrointestinal cancer, 64, 65 prostate cancer 66 and melanoma. 67 It has been reported that the inhibition of ILK by molecular inhibitors could block tumor growth and enhance gemcitabine-induced apoptosis in pancreatic cancer xenografts. 68 Consistent with this, the expression level of ILK had an impact on gemcitabine chemoresistance, whereas knockdown of ILK by siRNA increased the caspase-3-mediated apoptosis, and consequently resensitized the malignant cells to gemcitabine-induced cytotoxicity, which suggests the role of ILK as a determinant of pancreatic cancer resistance to gemcitabine. 69 The same research group reported how the siRNA induced suppression of an M2 subunit of ribonucleotide reductase (RRM2), which is associated with pancreatic cancer cell chemoresistance to gemcitabine 70 and with invasive potential of cancer cells.
71 RRM2-specific siRNA silenced the RRM2 gene expression in pancreatic cancer and attenuated gemcitabine chemoresistance by increasing apoptosis induced by gemcitabine and activating caspase-3, while simultaneously inhibiting tumor cells invasiveness with the downregulation of matrix metalloproteinase 9.
72,73
Ausora kinases (AURKA) are a family of oncogenic serine-threonine kinases that regulate mitotic spindle formation and centrosome maturation, chromosome segregation, 74 which are found to be overexpressed in tumor cell lines, including the pancreas. 75 More recently, it was demonstrated that deactivation of AURKA by antisense oligonucleotide can lead to decreased apoptosis. Therefore, AURKA is required to testify its potential as a therapeutic target in pancreatic cancer. In agreement with that, knockdown of AURKA implied by RNAi strongly inhibited the tumorigenicity of pancreatic cancer cells in vitro and in vivo, and eventual apoptosis was also induced. 76 A synergistically enhanced cytotoxicity of taxanes with the RNAi-mediated silence of AURKA was also confirmed in which AURKA knockdown might recover spindle checkpoint activity and thus increased the sensitivity of taxanes. 77 In view of the impact of overexpressed focal adhesion kinase (FAK) on tumor progression 75 and chemoresistance, 78 suppression of FAK expression was triggered by RNAi in vivo, 79 indicating that diminishing of FAK expression can potentiate gemcitabine-induced caspase-mediated apoptosis and enhance the susceptibility of pancreatic cancer cells to chemotherapeutically induced cytotoxicity.
More interestingly, in contrast to the enhancement of apoptosis by inhibition of FAK in colon cancer cell lines, 80 another report of inhibition of FAK expression 81 in pancreatic cancer demonstrated that FAK gene silenced by RNAi had no significant effect on tumor apoptosis and proliferation, however, promoted anoikis, a subset of apoptotic cell death, which had an association with increased caspase activation and decreased metastasis in the nude mouse model. Taken together, owing to the efficiency and specificity of siRNA in silencing the expression of target genes, sequence-specific gene downregulation mediated by RNAi has been carried out to investigate the therapeutic potential of RNAi for treatment of human diseases, especially for anticancer strategy. In addition to the therapeutic applications in pancreatic cancer mentioned above, a number of studies have been demonstrating that the RNAi can be directed against many other malignancies by selective knockdown of the cancer-associated genes as a promising anticancer intervention.
For instance, to inhibit cell growth and promote apoptosis for the treatment of prostate cancer, another most common cancer worldwide, De Schrijver et al. 82 reported that silencing the fatty acid synthase gene by siRNA significantly inhibited the prostate cancer cell line LNCaP growth and ultimately induced apoptosis. Depletion of polo-like kinase 1 gene expression with siRNA in prostate cancer cells also resulted in a significant decrease in cell viability and induction of apoptosis. 83 Furthermore, RNAi has also been developed to inhibit the increased lymphangiogenesis mediated by VEGF family, which contribute to the growth and metastasis of cancer. By constructing a siRNA-targeting VEGF-A, Wannenes et al. 84 demonstrated the knockdown of VEGF-A resulted in an impaired tumor growth and decreased microvessel density in vivo. Similarly, considering that VEGF-C is associated with tumor lymphangiogenesis and lymphnode metastasis, the effects of RNAimediated inhibition of VEGF-C were examined in vivo, indicating that silencing of VEGF-C by siRNA reduced the lymphangiogenesis and lymphnode and lung metastasis with an increased survival. 85 Therefore, RNAi-mediated knockdown of cancerassociated genes to inhibit tumor growth, lymphangiogenesis, metastasis, induce apoptosis and subsequently decrease the chemoradiotherapy resistance could be developed either as a stand-alone therapeutic modality or as an adjunct to conventional anticancer therapies. 13 In addition to determining the possible roles of RNAi in cancer treatment, RNAi-based therapies have been conducted to provide new alternatives for the treatment of infectious and neurologic diseases, including viral hepatitis, HIV infection and spinocerebellar ataxia. Most importantly, RNAi-based therapy has been performed in preclinical and phase I clinical trials to develop potential clinical applications of siRNA in various human diseases. 13, 14, 86 However, it should be noted that considering the challenges of blood stability, efficient delivery and intracellular uptake of siRNA in vivo, 86 there is a long way to go before successful clinical application of RNAibased gene therapy can be achieved.
RNAi and identification of 'loss of function' of genes in pancreatic cancer research
The promising applications of RNAi in pancreatic cancer research consist not only of the selection of potential targets for therapy, but also the identification of the 'loss of function' of endogenous genes, 87 including the oncogenes as well as the oncosuppressors, whose interactions are crucial to tumorigenesis. In general, functional genetic studies include forward (discovering the unknown genes underlying a known phenotype) and reverse (discovering the unknown function of a known gene) screens. 88, 89 RNAi might present the faster, simpler and specific alternative, compared to the research procedures in the past, with respect to disruption of a target gene to determine its function. Most importantly, the specificity and efficiency of RNAi in suppressing the gene's expression in vitro and in vivo also facilitate this exploration.
RNAi has been successfully used to knockdown the target genes in pancreatic cancer cell lines for reverse genetic screen to delineate the unknown functions of known genes. Transfected with the stably expressed siRNA, one pancreatic cancer cell line with the knockdown of target gene, for example the loss of gene function cell phenotype can be established for further research. Using the siRNA, Jazag et al. 87 reported that Smad4 knockdown (S4KD) pancreatic cancer cell lines were produced and subsequently stimulated with transforming growth factor (TGF-b) and analyzed with cDNA microarray technology. The cell lines were used as the loss of Smad4 function phenotype and the Smad4-independent target genes downstream of TGF-b, and related phenotypic changes were ultimately elucidated. In this study, some distinct target genes were detected and confirmed to be regulated downstream of the TGF-b signal. Especially, in the identified genes, 246 have not been reported previously as the downstream genes of TGF-b. So far, despite the fact that very few similar reports on pancreatic cancer research have been presented that give consideration to the multiple genetic abnormalities contributing to tumorigenesis of pancreatic cancer, there is no doubt that construction of loss of target gene function cell phenotype by RNAi will be a promising method to distinguish further the functions of known and unknown genes, which are involved in pancreatic cancer's emergence and progression.
Conclusions and future directions
To date, in accordance with specificity and effectiveness, RNAi has been confirmed to be a very important tool in silencing the target overexpressed genes, and proven to be a novel therapeutic approach for pancreatic cancer research in vitro and in vivo with a large degree of inhibition of tumor progression whether alone or combined with other therapeutic agents. However, a large amount of genetic abnormality has been identified in pancreatic cancer, demonstrating multiple genetic alternations, rather than a single one, accounting for the emergence of a tumor.
Simultaneously, as mentioned above, silencing one target gene by RNAi usually induces some interaction of another gene expression. Therefore, in cancer treatment, for improving the RNAi effectiveness, it might be necessary to try blocking several points or pathways, which can be achieved by accordingly constructing RNAi to direct against multiple related genes. Combining different targets or combination strategies with current modalities is presumed to be more intelligent for future successful cancer therapy. 90 For example, suppressing several mutated oncogenes and angiogenesis-, metastasis-or antiapoptosis-related genes cooperatively and simultaneously, such as VEGF, MMPs, IAPs, and so on. is one reasonable approach to block pancreatic cancer progression. Given the delineation of some more effective siRNA-expressing vectors, it is accessible, undoubtedly, to construct one such vector with different siRNAs in technology for specifically knocking down one more target genes or different sequence regions of one target gene simultaneously, named as RNAi cocktail. 91 However, in view of the delivery of siRNA, tissue-specific targeting may also be helpful for much more effective therapy by RNAi. Unfortunately, no relevant research on pancreatic cancer with a tissuespecific RNAi delivery system has been developed so far.
Meanwhile, another important application of RNAi is to define the 'loss of function' of endogenous genes. More recently, along with the successful construction of an RNAi library of short hairpin RNA (shRNA) expression vectors, for example, 89 one large library of RNAi can consist of about 28 000 shRNA expression cassettes targeting 9610 human and 5563 mouse genes, it provides an essential tool to knock down individual gene expression on a genome-wide scale, which can absolutely be anticipated to contribute to pancreatic cancer research as well.
Apart from the application of RNAi in cell lines, RNAi has also been used for the knock down of gene expression in animals and can produce the transgenic mice in a quicker and cheaper way 86 through functionally silencing of gene expression in stem cells and reconstituting organs or transgenic mice. 92, 93 Direct infection of single-cell embryos with RNAi lentiviruses can especially generate transgenic animals, which provides an efficient and broadly applicable approach to develop transgenic animals. 94 Hence, there may be a bright future for functional, genetic studies in pancreatic cancer using stem cell-derived transgenic null phenotype by RNAi.
